MANDELA Study Results at 18 Months after Heart Transplantation: Superior renal function with CNI-free everolimus over standard CNI-based regimen- a randomized, multi-center trial in de novo heart transplant recipients

被引：1
|
作者：
Barten, Markus J. [1 ]
Hirt, Stephan W. [1 ]
Garbade, Jens [1 ]
Bara, Christoph [1 ]
Doesch, Andreas [1 ]
Knosalla, Christoph [1 ]
Grinninger, Carola [1 ]
Stypmann, Joerg [1 ]
Sieder, Christian [2 ]
Junge, Martina [2 ]
Schulz, Uwe [1 ]
机构：
[1] Mandela, Study, Berlin, Germany
[2] Novartis, GmbH, Pharma, Nurnberg, Germany
来源：
TRANSPLANTATION | 2018年 / 102卷
关键词：
D O I：
10.1097/01.tp.0000543111.91427.46
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
591.1
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 19 条
  • [1] SUPERIOR RENAL FUNCTION WITH CNI-FREE EVEROLIMUS OVER STANDARD CNI-BASED REGIMEN: 18 MONTHS DATA FROM THE RANDOMIZED, MULTI-CENTER MANDELA TRIAL IN DE NOVO HEART TRANSPLANT RECIPIENTS
    Barten, M.
    Hirt, S.
    Bara, C.
    Garbade, J.
    Doesch, A.
    Knosalla, C.
    Grinninger, C.
    Stypmann, J.
    Sieder, C.
    Junge, M.
    Schulz, U.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 11 - 11
  • [2] Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients.
    Barten, M. J.
    Hirt, S. W.
    Garbade, J.
    Bara, C.
    Doesch, A.
    Knosalla, C.
    Grinninger, C.
    Stypmann, J.
    Sieder, C.
    Junge, M.
    Schulz, U.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 476 - 477
  • [3] A CNI-Free, Everolimus Based Regimen in De-Novo Heart Transplant Recipients Increases Albuminuria But Improves Glomerular Filtration Rate Compared With Conventional Immunosuppression
    Gustafsson, E.
    Andreassen, A.
    Arora, S.
    Andersson, B.
    Gude, E.
    Eiskjaer, H.
    Raadegran, G.
    Dellgren, G.
    Gullestad, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S281 - S281
  • [4] A Multi-Center, Randomized, Open-Label, Parallel Group Phase IV Trial Investigating the Outcome on Renal Function, Efficacy and Safety of CNI-Reduction or Elimination With Everolimus in De Novo Heart Transplant: Recipients: The MANDELA Study Design
    Deuse, T.
    Bara, C.
    Barten, M.
    Hirt, S.
    Doesch, A.
    Knosalla, C.
    Grinninger, C.
    Stypmann, J.
    Porstner, M.
    Wimmer, P.
    Schulz, U.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S86 - S86
  • [5] A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP PHASE IV TRIAL INVESTIGATING THE OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY OF CNI-REDUCTION OR ELIMINATION WITH EVEROLIMUS IN DE NOVO HEART TRANSPLANT RECIPIENTS: THE MANDELA STUDY DESIGN
    Deuse, T.
    Barten, C.
    Bara, C.
    Doesch, A.
    Hirt, S.
    Knosalla, C.
    Kaczmarek, I.
    Grinninger, C.
    Stypmann, J.
    Porstner, M.
    Wimmer, P.
    Lehmkuhl, H.
    Schulz, U.
    TRANSPLANT INTERNATIONAL, 2014, 27 : 46 - 46
  • [6] ATHENA STUDY OUTCOMES ON ALLOGRAFT FUNCTION AFTER 12 MONTHS WITH EVEROLIMUS-CNI VS TACROLIMUS-MPA REGIMEN IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Dragun, Duska
    Sommerer, Claudia
    Suwelack, Barbara
    Schenker, Peter
    Hauser, Ingeborg
    Witzke, Oliver
    Hugo, Christian
    Kamar, Nassim
    Merville, Pierre
    Junge, Martina
    Thaiss, Friedrich
    Nashan, Bjoern
    TRANSPLANT INTERNATIONAL, 2017, 30 : 562 - 562
  • [7] An open, single centre, prospective study to investigate a steroid free immunosuppressive regimen for de novo renal transplant recipients followed by a two arm randomisation to a CNI-sparing and a CNI-free maintenance immunosuppression after 3 months
    Oetti, T.
    Descoeudres, B.
    Burkhalter, F.
    Bachmann, A.
    Guerke, L.
    Mihatsch, M. J.
    Dickenmann, M.
    Steiger, J.
    SWISS MEDICAL WEEKLY, 2008, 138 (47-48) : 15S - 15S
  • [8] 12 MONTHS OUTCOMES ON ALLOGRAFT FUNCTION WITH EVEROLIMUS-CNI VS TACROLIMUS-MPA REGIMEN IN DE NOVO RENAL TRANSPLANT RECIPIENTS: THE ATHENA STUDY
    Merville, P.
    Kamar, N.
    Dragun, D.
    Sommerer, C.
    Suwelack, B.
    Schenker, P.
    Hauser, I. A.
    Witzke, O.
    Hugo, C.
    Junge, M.
    Thaiss, F.
    Nashan, B.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 15 - 15
  • [9] Exercise Capacity in De-Novo Heart Transplant Recipents With Everolimus Vs Conventional CNI Based Immunosuppresion. The Results of a Randomized Trial (SCHEDULE)
    Gude, E.
    Bartfay, S.
    Andersson, B.
    Sigurdardottir, V.
    Stueflotten, W.
    Gullestad, L.
    Andreassen, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S134 - S134
  • [10] EARLY EVEROLIMUS PLUS REDUCED TACROLIMUS VERSUS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS RESULTS IN SUPERIOR RENAL FUNCTION AND SUSTAINS OVER 24 MONTHS: RESULTS OF A RANDOMIZED TRIAL
    De Simone, P.
    Fischer, L.
    Kaiser, G.
    Jonas, S.
    Heise, M.
    Schemmer, P.
    Pascher, A.
    Schlitt, H.
    Paulus, E.
    Mertens, M.
    Duvoux, C.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 3 - 3
12